V001-BCMA

Phase 1Small molecule

V001-BCMA is one of 3 small molecule programs targeting Refractory Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Systemic Lupus ErythematosusActive, not recruiting

Refractory Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Refractory Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

GC012F

GGracell Biotechnologies (Shanghai) Co., Ltd.

Preclinical

1 2

V001-BCMA

TTongji Hospital

Phase 1

1 3

IM19 CAR-T Cells

BBeijing Immunochina Medical Science & Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Refractory Systemic Lupus Erythematosus

NCT07339540

Clinical

Trials by Indication[1]

Refractory Systemic Lupus Erythematosus1 trial

Clinical Study on the Safety and Efficacy of Targeted BCMA In Vivo LV Injection in the Treatment of Recurrent or Refractory Autoimmune Diseases

Active, not recruiting·TTongji Hospital·Phase 1·NCT07339540·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for V001-BCMA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — V001-BCMA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for V001-BCMA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTongji Hospital

V001-BCMA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Refractory Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News